Table 1.

US Food and Drug Administration approved therapies for the treatment of moderate-to-severe Alzheimer’s disease

Drug	Formulations	Dosing options	FDA recommended dosing for moderate AD	FDA recommended dosing for severe AD
Donepezil	Tablet	5, 10, 23 mg	5, 10, and 23 mg once daily	10 and 23 mg once daily
	Orally disintegrating tablet	5, 10 mg
Rivastigmine	Capsule	1.5, 3, 4.5, 6 mg	6–12 mg/d administered as twice daily	Not approved for severe AD
	Oral solution	2 mg/mL
	Transdermal patch	4.6, 9.5, 13.3 mg/24 h	9.5 or 13.3 mg/24 h once daily	13.3 mg/24 h once daily
Galantamine	Extended-release capsule	8, 16, 24 mg	16–24 mg once daily	Not approved for severe AD
	Tablet	4, 8, 12 mg	16–24 mg/d administered as twice daily
	Oral solution	4 mg/mL
Memantine	Extended-release capsule	7, 14, 21, 28 mg	28 mg once daily	28 mg once daily
	Tablet	5, 10 mg	20 mg/d administered as twice daily	20 mg/d administered as twice daily
	Oral solution	2 mg/mL
Memantine/donepezil FDC	Memantine extended-release/donepezil capsule	7/10 mg	28 mg memantine/10 mg donepezil once daily	28 mg memantine/10 mg donepezil once daily
		14/10 mg
		21/10 mg
		28/10 mg

Abbreviations: AD, Alzheimer’s disease; FDC, fixed-dose combination.